Global Adult Malignant Glioma Therapeutics Market Share, Price, Trends, Growth, Analysis, Key Players, Outlook, Report, Forecast 2023-2031

Adult Malignant Glioma Therapeutics Market

According to the report by Expert Market Research (EMR), the Global Adult Malignant Glioma Therapeutics Market Size reached a value of USD 2.01 billion in 2022. Aided by the rising prevalence of gliomas and the expanding research and development activities in cancer therapeutics, the market is projected to further grow at a CAGR of 9.2% between 2023 and 2031 to reach a value of USD 4.45 billion by 2031.

Malignant gliomas are the most common and aggressive type of primary brain tumours in adults, known for their rapid growth and high degree of invasiveness. The therapeutics for these tumours are an important focus for medical researchers and pharmaceutical companies due to the complexity of the disease and the limited efficacy of current treatment options.

The escalating prevalence of gliomas worldwide is a significant factor driving the global adult malignant glioma therapeutics market growth. This is accompanied by the increasing public awareness of the disease, leading to higher demand for effective treatments. Moreover, advances in genomics and personalised medicine are opening new avenues for the development of more targeted and effective therapies, which is further propelling market growth. The adult malignant glioma therapeutics market is also expanding as a result of the adoption of an unhealthy lifestyle, genetic modification or alteration, ageing populations, excessive radiation exposure, and familial histories of brain cancer.

The expansion of research and development activities in oncology is another crucial factor fuelling the adult malignant glioma therapeutics market demand. With investments in research and development reaching new heights, several promising therapies for malignant gliomas are under investigation, with many in advanced stages of clinical trials. These developments are likely to lead to more effective treatments in the coming years, thereby boosting the market’s growth.

Get a Free Sample Report with Table of Contents:

Moreover, advancements in drug delivery technologies for brain tumours are enhancing the effectiveness of therapeutics, thereby encouraging the global adult malignant glioma therapeutics market growth. Novel strategies are being developed to overcome the blood-brain barrier, a significant challenge in brain cancer treatment, and to deliver therapeutics more efficiently to the tumour site.

Furthermore, increasing collaborations among pharmaceutical companies, research institutions, and governments are expected to enhance research and development activities, accelerate regulatory approvals, and expedite the introduction of new therapies to the market. This, in turn, is likely to stimulate the global adult malignant glioma therapeutics market expansion.

Market Segmentation                            

The market can be divided based on diseases type, therapy type, drug class, route of administration, treatment centres, treatment channel, and region.

Market Breakup by Diseases Type

  • Glioblastoma Multiforme (GBM)
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
  • Others

Market Breakup by Therapy Type

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Tumour treating fields (TTF) Therapy
  • Combination Therapy
  • Others

Market Breakup by Drug Class

  • Alkylating Agents
  • Tyrosine Kinase Inhibitors
  • Checkpoint Inhibitors
  • Angiogenesis Inhibitors
  • Others

Market Breakup by Route of Administration

  • Oral 
  • Parentals
  • Others

Market Breakup by Treatment Centres

  • Hospitals
  • Speciality Clinics
  • Ambulatory Surgical Centres
  • Cancer Research Institutes
  • Others

Market Breakup by Treatment Channel

  • Public
  • Private

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global adult malignant glioma therapeutics companies. Some of the major key players explored in the report by Expert Market Research are as follows:

  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Bayer AG
  • Merck & Co., Inc.
  • Allergan
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Abbott
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Amneal Pharmaceuticals LLC.
  • Genetech Inc.
  • Emcure

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Leave a Reply

Your email address will not be published. Required fields are marked *